Front. Immunol.
Frontiers in Immunology
Front. Immunol.
1664-3224
Frontiers Media S.A.
10.3389/fimmu.2023.1219757
Immunology
Correction
Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
Wang
Guanyun
1
2
†
Zhang
Wenwen
3
†
Luan
Xiaohui
1
4
Wang
Zhanbo
5
Liu
Jiajin
1
Xu
Xiaodan
1
Zhang
Jinming
1
Xu
Baixuan
1
Lu
Shichun
3
*
Wang
Ruimin
1
*
Ma
Guangyu
1
*
1
Department of Nuclear Medicine, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
2
Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China
3
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People’s Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People’s Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People’s Liberation Army, Beijing, China
4
Graduate School, Medical School of Chinese People’s Liberation Army (PLA), Beijing, China
5
Department of Pathology, The First Medical Centre, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China
Edited and Reviewed by: Takaji Matsutani, Repertoire Genesis, Inc., Japan
*Correspondence: Guangyu Ma, mgy301@163.com; Ruimin Wang, wrm@yeah.net; Shichun Lu, lusc_301@163.com
†These authors have contributed equally to this work
22
05
2023
2023
14
1219757
09
05
2023
12
05
2023
Copyright © 2023 Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma
2023
Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy by Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023). Front. Immunol. 14:1151967. doi: 10.3389/fimmu.2023.1151967
unresectable hepatocellular carcinoma
conversion therapy
major pathological response
prognosis
18F-FDG PET
section-in-acceptance
Cancer Immunity and Immunotherapy
In the published article, there was an error in the formula in the manuscript.
A correction has been made to Materials and Methods, Image analysis, Paragraph 2. This sentence previously stated:
“The percentages of post-treatment changes in metabolic parameters were calculated as follows:
Δ
SUVmax
(
%
)
=
SUVmax of pre-treatment
−
SUVmax of post-treatment
SUVmax of pretreatment
×
100
%
ΔTLR
(
%
)
=
TLR of pre-treatment
−
TLR of post-treatment
TLR of pre-treatment
×
100
%
ΔPLR
(
%
)
=
PLR of pre-treatment
−
PLR of post-treatment
PLR of pre-treatment
×
100
%
”
The corrected sentence appears below:
“The percentages of post-treatment changes in metabolic parameters were calculated as follows:
Δ
SUVmax
(
%
)
=
SUVmax of post-treatment
−
SUVmax of pre-treatment
SUV of pre-treatment
×
100
%
ΔTLR
(
%
)
=
TLR of post-treatment
−
TLR of pre-treatment
TLR of pre-treatment
×
100
%
ΔPLR
(
%
)
=
PLR of post-treatment
−
PLR of pre-treatment
PLR of pre-treatment
×
100
%
”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.